NDA 016092 · Bausch
Edecrin
Ethacrynic Acid · Oral · Loop Diuretic
NovelLast checked: Nov 20, 2026Latest source record: Mar 30, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1967
Jan 10, 1967
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
1 Phase 3, 1 recruiting
FAERS reports
553
400 serious, 66 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2023.
INDICATIONS AND USAGE Ethacrynic acid is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous ethacrynate sodium is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 10, 1967 Original approval · Type 1 - New Molecular Entity
2 products under this application
- EDECRIN · ETHACRYNIC ACID 25MG · TABLET, ORAL · Prescription · TE AB
- EDECRIN · ETHACRYNIC ACID 50MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Ethacrynic Acid" as an intervention, any sponsor and status, largest first.
- Furosemide Versus Ethacrynic Acid in Children With Congenital Heart DiseasePivotal-lookingCompleted
Bambino Gesù Hospital and Research InstituteAcademic, hospital or other
NCT01628731 · 74 participants · Start Oct 2012 · Primary completion Jul 2013
Drug: furosemide; ethacrynic acid · For: Fluid Overload
Sites: Rome, Italy
- Phase 0 Study to Define the Effect of Low Dose Ethacrynic Acid on Total Glutathione (GSH) Levels and Glutathione S-transferase (GST) ActivityNot yet recruiting
University of Vermont Medical CenterAcademic, hospital or other
NCT07943000 · 40 participants (planned) · Start Jan 2029 · Primary completion Jan 2029
Drug: ethacrynic acid · For: Healthy Volunteers; Redox Biology
Eugene Lee, MDAcademic, hospital or other
NCT02852564 · 12 participants · Start Aug 2016 · Primary completion Jul 2017
Drug: Ethacrynic Acid · For: Bladder Cancer
Sites: Kansas City, Kansas
Molly WalshAcademic, hospital or other
NCT02051946 · 9 participants · Start May 2014 · Primary completion Oct 2015
Drug: ethacrynic acid injection; balanced salt solution · For: Glaucoma
Sites: Durham, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug reaction with eosinophilia and systemic symptoms59
- off label use52
- nausea48
- dyspnoea43
- drug ineffective35
- acute kidney injury33
- diarrhoea33
- drug hypersensitivity33
- fatigue32
- vomiting32
- asthenia26
- death26
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 4 |
| 2006 | 9 |
| 2007 | 7 |
| 2008 | 9 |
| 2009 | 7 |
| 2010 | 12 |
| 2011 | 18 |
| 2012 | 31 |
| 2013 | 18 |
| 2014 | 15 |
| 2015 | 23 |
| 2016 | 27 |
| 2017 | 39 |
| 2018 | 30 |
| 2019 | 40 |
| 2020 | 28 |
| 2021 | 53 |
| 2022 | 43 |
| 2023 | 46 |
| 2024 | 25 |
| 2025 | 27 |
| 2026 | 33 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Edecrin (Ethacrynic Acid)
2024 spending
$587K
Beneficiaries
53
250 claims
Per beneficiary
$11,082
$23.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $920,791 |
| 2021 | $765,609 |
| 2022 | $675,566 |
| 2023 | $517,004 |
| 2024 | $587,364 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Studies on the mechanism and characteristics of action of a uricosuric diuretic, indacrinone (MK-196).
Brooks BA, Blair EM, Finch R, et al. · Br J Clin Pharmacol 1980 · Clinical Trial, Randomized Controlled Trial
- Excretion of urinary casts after the administration of diuretics.
Imhof PR, Hushak J, Schumann G, et al. · Br Med J 1972 · Clinical Trial, Controlled Clinical Trial
- Clinical comparison of frusemide with bendrofluazide, mersalyl, and ethacrynic acid.
Stewart JH, Edwards KD · Br Med J 1965 · Clinical Trial, Comparative Study
- Loop diuretics for patients receiving blood transfusions.
Sarai M, Tejani AM · Cochrane Database Syst Rev 2015 · Meta-Analysis, Systematic Review
- Assessment of the Potential for Veverimer Drug-Drug Interactions.
Parsell D, Shao J, Guttendorf R, et al. · Drug Metab Dispos 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A controlled clinical trial comparing the diuretic ethacrynic acid and furosemide in patients with congestive heart failure.
Chugh KS, Gupta KK, Chaudhury RR · Indian J Med Res 1969 · Clinical Trial, Comparative Study
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.